|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DIS3 |
Gene summary for DIS3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DIS3 | Gene ID | 22894 |
| Gene name | DIS3 homolog, exosome endoribonuclease and 3'-5' exoribonuclease | |
| Gene Alias | 2810028N01Rik | |
| Cytomap | 13q21.33 | |
| Gene Type | protein-coding | GO ID | GO:0000288 | UniProtAcc | Q9Y2L1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 22894 | DIS3 | LZE4T | Human | Esophagus | ESCC | 6.04e-05 | -3.73e-03 | 0.0811 |
| 22894 | DIS3 | LZE5T | Human | Esophagus | ESCC | 3.60e-06 | 6.38e-02 | 0.0514 |
| 22894 | DIS3 | LZE7T | Human | Esophagus | ESCC | 3.38e-05 | 3.05e-01 | 0.0667 |
| 22894 | DIS3 | LZE8T | Human | Esophagus | ESCC | 1.93e-05 | -1.07e-01 | 0.067 |
| 22894 | DIS3 | LZE20T | Human | Esophagus | ESCC | 2.64e-03 | -1.90e-02 | 0.0662 |
| 22894 | DIS3 | LZE21D1 | Human | Esophagus | HGIN | 1.74e-02 | -2.36e-02 | 0.0632 |
| 22894 | DIS3 | LZE22T | Human | Esophagus | ESCC | 2.62e-04 | 6.11e-03 | 0.068 |
| 22894 | DIS3 | LZE24T | Human | Esophagus | ESCC | 6.01e-11 | 2.40e-01 | 0.0596 |
| 22894 | DIS3 | LZE21T | Human | Esophagus | ESCC | 7.57e-03 | -9.83e-03 | 0.0655 |
| 22894 | DIS3 | LZE6T | Human | Esophagus | ESCC | 1.19e-02 | -7.71e-02 | 0.0845 |
| 22894 | DIS3 | P1T-E | Human | Esophagus | ESCC | 5.00e-12 | 2.94e-01 | 0.0875 |
| 22894 | DIS3 | P2T-E | Human | Esophagus | ESCC | 1.00e-20 | 2.22e-01 | 0.1177 |
| 22894 | DIS3 | P4T-E | Human | Esophagus | ESCC | 1.07e-07 | 3.80e-02 | 0.1323 |
| 22894 | DIS3 | P5T-E | Human | Esophagus | ESCC | 1.37e-07 | 1.48e-02 | 0.1327 |
| 22894 | DIS3 | P8T-E | Human | Esophagus | ESCC | 3.70e-15 | 4.22e-01 | 0.0889 |
| 22894 | DIS3 | P9T-E | Human | Esophagus | ESCC | 1.88e-09 | 2.14e-01 | 0.1131 |
| 22894 | DIS3 | P10T-E | Human | Esophagus | ESCC | 6.00e-23 | 3.00e-01 | 0.116 |
| 22894 | DIS3 | P11T-E | Human | Esophagus | ESCC | 6.89e-13 | 3.22e-01 | 0.1426 |
| 22894 | DIS3 | P12T-E | Human | Esophagus | ESCC | 8.51e-11 | 1.76e-01 | 0.1122 |
| 22894 | DIS3 | P15T-E | Human | Esophagus | ESCC | 1.39e-12 | 1.55e-01 | 0.1149 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004348812 | Lung | AIS | regulation of mRNA stability | 30/1849 | 158/18723 | 3.46e-04 | 6.25e-03 | 30 |
| GO:006101312 | Lung | AIS | regulation of mRNA catabolic process | 31/1849 | 166/18723 | 3.77e-04 | 6.61e-03 | 31 |
| GO:004348712 | Lung | AIS | regulation of RNA stability | 31/1849 | 170/18723 | 5.76e-04 | 8.97e-03 | 31 |
| GO:006101412 | Lung | AIS | positive regulation of mRNA catabolic process | 19/1849 | 87/18723 | 7.09e-04 | 1.04e-02 | 19 |
| GO:001058612 | Lung | AIS | miRNA metabolic process | 9/1849 | 27/18723 | 7.88e-04 | 1.11e-02 | 9 |
| GO:000640112 | Lung | AIS | RNA catabolic process | 44/1849 | 278/18723 | 1.15e-03 | 1.47e-02 | 44 |
| GO:006115712 | Lung | AIS | mRNA destabilization | 18/1849 | 84/18723 | 1.22e-03 | 1.55e-02 | 18 |
| GO:005077912 | Lung | AIS | RNA destabilization | 18/1849 | 88/18723 | 2.13e-03 | 2.30e-02 | 18 |
| GO:001058711 | Lung | AIS | miRNA catabolic process | 5/1849 | 12/18723 | 4.08e-03 | 3.65e-02 | 5 |
| GO:190331132 | Lung | MIAC | regulation of mRNA metabolic process | 45/967 | 288/18723 | 2.75e-11 | 4.70e-08 | 45 |
| GO:000989632 | Lung | MIAC | positive regulation of catabolic process | 54/967 | 492/18723 | 1.42e-07 | 3.64e-05 | 54 |
| GO:000641733 | Lung | MIAC | regulation of translation | 51/967 | 468/18723 | 3.94e-07 | 6.52e-05 | 51 |
| GO:003133132 | Lung | MIAC | positive regulation of cellular catabolic process | 46/967 | 427/18723 | 2.00e-06 | 2.44e-04 | 46 |
| GO:004348831 | Lung | MIAC | regulation of mRNA stability | 23/967 | 158/18723 | 6.62e-06 | 6.29e-04 | 23 |
| GO:004348731 | Lung | MIAC | regulation of RNA stability | 24/967 | 170/18723 | 7.20e-06 | 6.53e-04 | 24 |
| GO:006101331 | Lung | MIAC | regulation of mRNA catabolic process | 23/967 | 166/18723 | 1.52e-05 | 1.07e-03 | 23 |
| GO:000640231 | Lung | MIAC | mRNA catabolic process | 28/967 | 232/18723 | 2.65e-05 | 1.66e-03 | 28 |
| GO:190331322 | Lung | MIAC | positive regulation of mRNA metabolic process | 17/967 | 118/18723 | 1.17e-04 | 4.92e-03 | 17 |
| GO:006115722 | Lung | MIAC | mRNA destabilization | 13/967 | 84/18723 | 3.55e-04 | 1.04e-02 | 13 |
| GO:006101422 | Lung | MIAC | positive regulation of mRNA catabolic process | 13/967 | 87/18723 | 5.03e-04 | 1.34e-02 | 13 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301810 | Esophagus | HGIN | RNA degradation | 27/1383 | 79/8465 | 7.73e-05 | 9.00e-04 | 7.15e-04 | 27 |
| hsa0301815 | Esophagus | HGIN | RNA degradation | 27/1383 | 79/8465 | 7.73e-05 | 9.00e-04 | 7.15e-04 | 27 |
| hsa0301824 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
| hsa0301834 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
| hsa030182 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
| hsa030183 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
| hsa030189 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
| hsa0301814 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| DIS3 | TFH | Endometrium | EEC | TFIP11,SNHG9,NBEAL1, etc. | 5.05e-02 |  |
| DIS3 | TH17 | Endometrium | EEC | TFIP11,SNHG9,NBEAL1, etc. | 3.02e-02 | |
| DIS3 | TREG | Lung | IAC | H1F0,VDR,FUT11, etc. | 2.01e-01 |  |
| DIS3 | MAIT | Lung | IAC | H1F0,VDR,FUT11, etc. | 4.77e-05 | |
| DIS3 | BMEM | Lung | IAC | H1F0,VDR,FUT11, etc. | 6.06e-05 | |
| DIS3 | MDSC | Lung | IAC | H1F0,VDR,FUT11, etc. | 9.15e-05 | |
| DIS3 | INFIB | Thyroid | ADJ | ZC3H11A,CHMP4C,MTCO2P12, etc. | 4.20e-01 |  |
| DIS3 | ICAF | Thyroid | goiters | ZC3H11A,CHMP4C,MTCO2P12, etc. | 2.22e-16 |  |
| DIS3 | MSC.MVA | Thyroid | Healthy | ZC3H11A,CHMP4C,MTCO2P12, etc. | 3.56e-02 |  |
| DIS3 | ICAF | Thyroid | Healthy | ZC3H11A,CHMP4C,MTCO2P12, etc. | 0.00e+00 | |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DIS3 | SNV | Missense_Mutation | c.2066N>A | p.Arg689Gln | p.R689Q | Q9Y2L1 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DIS3 | SNV | Missense_Mutation | c.1001T>C | p.Val334Ala | p.V334A | Q9Y2L1 | protein_coding | tolerated(0.82) | benign(0) | TCGA-BH-A0DX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| DIS3 | SNV | Missense_Mutation | rs760670933 | c.616G>A | p.Glu206Lys | p.E206K | Q9Y2L1 | protein_coding | tolerated(0.33) | benign(0.149) | TCGA-BH-A1F8-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| DIS3 | SNV | Missense_Mutation | c.1662N>G | p.Asp554Glu | p.D554E | Q9Y2L1 | protein_coding | tolerated(0.21) | benign(0.018) | TCGA-BH-A1FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| DIS3 | insertion | Frame_Shift_Ins | novel | c.2032dupA | p.Ile678AsnfsTer3 | p.I678Nfs*3 | Q9Y2L1 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| DIS3 | deletion | Frame_Shift_Del | novel | c.527delN | p.Asn176MetfsTer10 | p.N176Mfs*10 | Q9Y2L1 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| DIS3 | SNV | Missense_Mutation | novel | c.2257T>C | p.Tyr753His | p.Y753H | Q9Y2L1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DIS3 | SNV | Missense_Mutation | rs757306363 | c.1831C>T | p.Arg611Cys | p.R611C | Q9Y2L1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DIS3 | SNV | Missense_Mutation | novel | c.2164N>A | p.Ala722Thr | p.A722T | Q9Y2L1 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| DIS3 | SNV | Missense_Mutation | c.2348C>T | p.Ala783Val | p.A783V | Q9Y2L1 | protein_coding | deleterious(0.01) | benign(0.247) | TCGA-AA-3819-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |